QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

Breast Cancer Research

Volumn 11, Issue 3, 2009, Pages

  Kalra, Jessica ^a,b   Warburton, Corinna ^a   Fang, Karen ^a,b   Edwards, Lincoln ^a,b   Daynard, Tim ^c   Waterhouse, Dawn ^a,b   Dragowska, Wieslawa ^a   Sutherland, Brent W ^a   Dedhar, Shoukat ^a,b   Gelmon, Karen ^a   Bally, Marcel ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c QLT Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; F ACTIN; INTEGRIN LINKED KINASE; NAVELBINE; PACLITAXEL; PROTEIN KINASE B; QLT 0267; SMALL MOLECULE TRANSPORT AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; ACTIN; ANTINEOPLASTIC AGENT; INTEGRIN-LINKED KINASE; PROTEIN SERINE THREONINE KINASE; TAXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOARCHITECTURE; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN SECRETION; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ACTINS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TAXOIDS;

EID: 74049103772     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2252     Document Type: Article

References (54)

1. Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 2001, 155:505-510. 2198863, 11696562, 10.1083/jcb.200108077.
2. Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005, 65:1497-1504. 10.1158/0008-5472.CAN-04-2940, 15735038.
3. Yoganathan TN, Costello P, Chen X, Jabali M, Yan J, Leung D, Zhang Z, Yee A, Dedhar S, Sanghera J. Integrin-linked kinase (ILK): a "hot" therapeutic target. Biochem Pharmacol 2000, 60:1115-1119. 10.1016/S0006-2952(00)00444-5, 11007949.
4. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005, 5:51-63. 10.1038/nrc1524, 15630415.
5. Wu C. Integrin-linked kinase and PINCH: partners in regulation of cell-extracellular matrix interaction and signal transduction. J Cell Sci 1999, 112(Pt 24):4485-4489.
6. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP, Dedhar S. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001, 276:27462-27469. 10.1074/jbc.M102940200, 11313365.
7. Deng JT, Sutherland C, Brautigan DL, Eto M, Walsh MP. Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase. Biochem J 2002, 367:517-524. 1222907, 12144526, 10.1042/BJ20020522.
8. Yamaji S, Suzuki A, Sugiyama Y, Koide Y, Yoshida M, Kanamori H, Mohri H, Ohno S, Ishigatsubo Y. A novel integrin-linked kinase-binding protein, affixin, is involved in the early stage of cell-substrate interaction. J Cell Biol 2001, 153:1251-1264. 2192033, 11402068, 10.1083/jcb.153.6.1251.
9. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC, Dedhar S. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 1996, 379:91-96. 10.1038/379091a0, 8538749.
10. Mulrooney J, Foley K, Vineberg S, Barreuther M, Grabel L. Phosphorylation of the beta1 integrin cytoplasmic domain: toward an understanding of function and mechanism. Exp Cell Res 2000, 258:332-341. 10.1006/excr.2000.4964, 10896784.
11. Ahmed N, Oliva K, Rice GE, Quinn MA. Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. Clin Cancer Res 2004, 10:2415-2420. 10.1158/1078-0432.CCR-03-0042, 15073119.
12. Intaraprasong P, Assi K, Owen DA, Huntsman DG, Chung SW, Scudamore CH, Yoshida EM, Salh B. Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. Anticancer Res 2007, 27:4371-4376.
13. Lu H, Fedak PW, Dai X, Du C, Zhou YQ, Henkelman M, Mongroo PS, Lau A, Yamabi H, Hinek A, et al. Integrin-linked kinase expression is elevated in human cardiac hypertrophy and induces hypertrophy in transgenic mice. Circulation 2006, 114:2271-2279. 10.1161/CIRCULATIONAHA.106.642330, 17088456.
14. Okamura M, Yamaji S, Nagashima Y, Nishikawa M, Yoshimoto N, Kido Y, Iemoto Y, Aoki I, Ishigatsubo Y. Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol 2007, 38:1081-1091. 10.1016/j.humpath.2007.01.003, 17442374.
15. Qi XP, Fang L, Lin KX, Xu LG, Yan L, Li F, Dai XW. [Expression of integrin-linked kinase in prostate cancer and its significance]. Zhonghua Nan Ke Xue 2005, 11:34-37.
16. Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D, Martinka M, Li G. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 2003, 9:4409-4414.
17. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 2000, 97:3207-3212. 16217, 10716737, 10.1073/pnas.060579697.
18. Attwell S, Roskelley C, Dedhar S. The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 2000, 19:3811-3815. 10.1038/sj.onc.1203711, 10949937.
19. Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J, Dedhar S. Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J Biol Chem 1997, 272:13937-13944. 10.1074/jbc.272.21.13937, 9153256.
20. Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, Wheeler J, Gleave M, Sanghera J, Dedhar S. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 2004, 5:79-90. 10.1016/S1535-6108(03)00281-2, 14749128.
21. Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, et al. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK). Mol Cancer Ther 2008, 7:59-70. 10.1158/1535-7163.MCT-07-0329, 18202010.
22. Kretzler PLM. (INC. KP ed., A61K31/415 edition. Canada 2002,
23. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 2005, 24:3596-3605. 10.1038/sj.onc.1208427, 15782140.
24. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res 2006, 66:393-403. 10.1158/0008-5472.CAN-05-2304, 16397254.
25. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther 2006, 5:645-654. 10.1158/1535-7163.MCT-05-0099, 16546979.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55. 10.1016/0065-2571(84)90007-4, 6382953.
27. Leonessa F, Green D, Licht T, Wright A, Wingate-Legette K, Lippman J, Gottesman MM, Clarke R. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br J Cancer 1996, 73:154-161.
28. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, et al. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res 2004, 2:606-619.
29. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Rijn M, Waltham M, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235. 10.1038/73432, 10700174.
30. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells - a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007, 104:13-19. 10.1007/s10549-006-9392-8, 17004106.
31. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004, 64:3479-3485. 10.1158/0008-5472.CAN-3299-2, 15150101.
32. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 17157791.
33. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681. 10.1124/pr.58.3.10, 16968952.
34. Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 2001, 37:69-82. 10.1016/S1040-8428(00)00110-4, 11164721.
35. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006, 5:1854-1863. 10.1158/1535-7163.MCT-06-0118, 16891472.
36. Rosenblum MD, Shivers RR. 'Rings' of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere. Comp Biochem Physiol C Toxicol Pharmacol 2000, 125:121-131.
37. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El-Naggar A, Bekele BN, Mills GB, Myers JN. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 2005, 4:1146-1156. 10.1158/1535-7163.MCT-05-0078, 16093430.
38. Pegram MD. Docetaxel and herceptin: foundation for future strategies. Oncologist 2001, 6(Suppl 3):22-25. 10.1634/theoncologist.6-suppl_3-22, 11346681.
39. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005, 6:229-239. 10.1016/S1470-2045(05)70094-2, 15811618.
40. Yoo GH, Lin HS, Iskander AJ, Piechocki MP, Oliver J, Kewson D, Lonardo F, Tainsky MA, Kim HR, Kim H, Ensley JF. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study. Laryngoscope 2005, 115:1938-1946. 10.1097/01.mlg.0000177456.90870.94, 16319602.
41. Fabbri F, Amadori D, Carloni S, Brigliadori G, Tesei A, Ulivi P, Rosetti M, Vannini I, Arienti C, Zoli W, Silvestrini R. Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J Cell Physiol 2008, 217:494-501. 10.1002/jcp.21522, 18615564.
42. Mhaidat NM, Zhang XD, Jiang CC, Hersey P. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res 2007, 13:1308-1314. 10.1158/1078-0432.CCR-06-2216, 17317842.
43. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999, 44:355-361. 10.1007/s002800050989, 10501907.
44. Somasiri A, Howarth A, Goswami D, Dedhar S, Roskelley CD. Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J Cell Sci 2001, 114:1125-1136.
45. Filipenko NR, Attwell S, Roskelley C, Dedhar S. Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX. Oncogene 2005, 24:5837-5849. 10.1038/sj.onc.1208737, 15897874.
46. Graness A, Giehl K, Goppelt-Struebe M. Differential involvement of the integrin-linked kinase (ILK) in RhoA-dependent rearrangement of F-actin fibers and induction of connective tissue growth factor (CTGF). Cell Signal 2006, 18:433-440. 10.1016/j.cellsig.2005.05.011, 15970428.
47. Fielding AB, Dobreva I, Dedhar S. Beyond focal adhesions: integrin-linked kinase associates with tubulin and regulates mitotic spindle organization. Cell Cycle 2008, 7:1899-1906.
48. Bijman MN, van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW, Boven E. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther 2006, 5:2348-2357. 10.1158/1535-7163.MCT-06-0242, 16985069.
49. Ramos J, Sirisawad M, Miller R, Naumovski L. Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation. Mol Cancer Ther 2006, 5:1176-1182. 10.1158/1535-7163.MCT-05-0280, 16731749.
50. Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, Koster F, Heinrich E, Halmos G, Rick FG, Kannadka C, et al. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci USA 2006, 103:14513-14518. 1599991, 16983095, 10.1073/pnas.0605309103.
51. Maddika S, Ande SR, Wiechec E, Hansen LL, Wesselborg S, Los M. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci 2008, 121:979-988. 10.1242/jcs.009530, 18354084.
52. Byzova TV, Rabbani R, D'Souza SE, Plow EF. Role of integrin alpha(v)beta3 in vascular biology. Thromb Haemost 1998, 80:726-734.
53. Watanabe M, Fujioka-Kaneko Y, Kobayashi H, Kiniwa M, Kuwano M, Basaki Y. Involvement of integrin-linked kinase in capillary/tube-like network formation of human vascular endothelial cells. Biol Proced Online 2005, 7:41-47. 1190378, 16136223, 10.1251/bpo104.
54. Murtagh J, Lu H, Schwartz EL. Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation. Cancer Res 2006, 66:8192-8199. 10.1158/0008-5472.CAN-06-0748, 16912198.